The recent controversy over declarations by the Food and Drug Administration related to federal pre-emption of state product liability laws has brought into the crucible of high-stakes tort litigation a hitherto relatively obscure area of administrative procedure.

With the FDA taking a considerably more pro-pre-emption stance of late, questions regarding judicial deference to agency — and particularly FDA — interpretations of their organic statutes and regulations are becoming more important. In light of this fact, this article examines the core precedent applicable to determining the extent of judicial deference to FDA decision-making.

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Advance® Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]